Svetlana D. Pack, Ph.D.

Svetlana D. Pack, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - 2S235 (office) / 3S255 (Lab)
  • Bethesda, MD 20892
  • 301-480-4204
  • 301-339-4531
Laboratory of Pathology


Dr. Pack's research interests range from molecular and cell biology to clinical investigations and specifically include mechanisms of tumor formation, aneuploidy, apoptosis, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies and development of the novel clinical diagnostics. She studied hereditary neoplastic syndromes: von Hippel-Lindau syndrome (VHL), multiple Endocrine Neoplasia, type 1 and 2, (MEN-1, MEN-2), Hereditary Papillary Renal Cell carcinoma (HPRCC), Carney Complex (CC), sporadic cancer, elucidating molecular mechanisms of tumor and cancer initiation and progression, the development of clinical cytogenetic diagnostic assays; and anticancer molecular targets.

Areas of Expertise

1) cancer genetics, 2) cytogenetics, 3) molecular diagnostics


Selected Publications

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U
Cold Spring Harb Mol Case Stud. 2(6): 2016. [ Journal Article ]

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

Olanich ME, Sun W, Hewitt SM, Abdullaev Z, Pack SD, Barr FG.
Clin Cancer Res. 21(21): 4947-59, 2015. [ Journal Article ]

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G
J Clin Oncol. 33(9): 1000-7, 2015. [ Journal Article ]

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma

Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M.
N Engl J Med.. 6/377(1): 89-91, 2017. [ Journal Article ]

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leuk Lymphoma

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH.
Leuk Lymphoma. June 22: 1-4, 2017. [ Journal Article ]


Research Biologist
Zied Abdullaev, Ph.D.
Lead Medical Technologist
Shannon Skarshaug, M.S., CG (ASCP)
Medical Technologist
Valerie Zgonc, B.S., CG (ASCP)